Trials / Active Not Recruiting
Active Not RecruitingNCT04860947
Assessment of NfL and GFAP Levels, Atrophy of the Macula GCC by OCT and Whole Brain Atrophy by MRI to Predict Evolution of Neurological Disability in MS Patients
Assessment of Serum Neurofilament-light Chain (NfL) and Glial Fibrillary Acidic Protein (GFAP) Levels, Atrophy of the Macular Ganglion Cell Complex (GCC) by Optical Coherence Tomography (OCT) and Whole Brain Atrophy by MRI to Predict Evolution of Neurological Disability in Multiple Sclerosis Patients
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (actual)
- Sponsor
- Centre Hospitalier Universitaire de Nīmes · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The investigators hypothesize that serum neurofilament-light chain (NfL) levels at baseline and decrease of the macular ganglion cell complex (GCC) thickness at one year vs. baseline are as good as progression of whole brain atrophy at one year vs. baseline to predict later evolution of neurological disability in multiple sclerosis patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Brain MRI | * Axial DWI with ADC card * Axial 2D TSE T2/DP or 3DT2 * Gadolinium injection (0.1 mmol/kg) * 3D Fluid-attenuated inversion recovery * 3D T1 with Gadolinium injection. |
| DIAGNOSTIC_TEST | Spinal Cord MRI | Sagittal T2 Sagittal T1 with Gadolinium injection |
| DIAGNOSTIC_TEST | Retinal imaging | spectral-domain high definition optical coherence tomography |
Timeline
- Start date
- 2019-06-25
- Primary completion
- 2026-06-01
- Completion
- 2026-06-01
- First posted
- 2021-04-27
- Last updated
- 2024-02-26
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT04860947. Inclusion in this directory is not an endorsement.